Dexmedetomidine plus sufentanil for pediatric flexible bronchoscopy: A retrospective clinical trial
PDF | HTML | How to cite
Metrics: PDF 1458 views | HTML 1852 views | ?
Xiujing Dang1,*, Weidong Hu1,*, Zhendong Yang1 and Shiyu Su2
1Department of Anesthesiology, Qilu Children’s Hospital of Shandong University, Jinan, Shandong, 250022, P.R. China
2Department of Anesthesiology, The Fifth People’s Hospital of Jinan, Jinan, Shandong, 250022, P.R. China
*These authors have contributed equally to this work
Shiyu Su, email: [email protected]
Keywords: dexmedetomidine, sufentanil, pediatric, flexible bronchoscopy
Received: January 17, 2017 Accepted: March 22, 2017 Published: April 17, 2017
Several studies have reported the use of dexmedetomidine (DEX) plus opioids for flexible bronchoscopy in both adults and children. To determine whether DEX plus sufentanil (SF) is safe for children, 142 children undergoing flexible bronchoscopy were assigned to one of three groups, each of which received the same SF loading dose and similar DEX and SF maintenance doses, but different loading doses of DEX: DS1 (DEX 0.5 μg·kg–1), DS2 (DEX 1.0 μg·kg–1), and DS3 (DEX 1.5 μg·kg–1). The Ramsay sedation scale was maintained at 3 in all groups. Results showed that anesthesia onset time was shorter, and the perioperative hemodynamic profile was more stable, in the DS3 group. The number of intraoperative movements was also lowest in the DS3 group. The time to first dose of rescue midazolam and lidocaine was significantly longer, but the total corresponding accumulated doses were lower in the DS3 group. Although the time to recovery prior to discharge from the post anesthesia care unit was longer, the overall incidence of tachycardia was lower in the DS3 group, and it received the highest bronchoscopist satisfaction score among the three groups. We therefore conclude that high-dose DEX plus SF can be safely and efficaciously used in children undergoing flexible bronchoscopy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.